Search
Hengrui Medicine's subsidiary, Guangdong Hengrui, has recently obtained the official Drug Clinical Trial Approval Notice for SHR-2173 Injection from the National Medical Products Administration. This approval paves the way for the initiation of clinical trials. SHR-2173 is an innovative therapeutic biological product independently developed by Hengrui Medicine, possessing potent anti-inflammatory and immunosuppressive properties. The drug is anticipated to lower antibody levels and alleviate symptoms in patients suffering from primary membranous nephropathy, thereby offering a groundbreaking treatment alternative. Notably, there are currently no comparable medications available on the market or in the clinical development pipeline, either domestically or internationally.
-
C114 Communication Network -
Communication Home
